Purchase Order 75N95024P00518
Award Date 9/11/24
Potential Completion Date 9/10/25
Potential Value $184K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse awarded a $105,000 firm fixed price purchase order to New York Stem Cell Foundation Inc. as the prime contractor. The contract is to support the agency's research efforts and will be performed in New York, New York over a one year period from September 2023 through September 2024. No major subcontractors or set aside designations were indicated. The National Institute on Drug Abuse...
- The National Institute on Drug Abuse (NIDA) awarded a $164,226.56 firm-fixed-price purchase order to Infinity Biologix LLC on September 18, 2020, for induced pluripotent stem cell (iPSC) lines for derivation study. The contract was executed as a pre-solicitation opportunity that closed on July 29, 2019, with performance to be completed by January 31, 2022. Work is to be performed in Piscataway, New Jersey, where Infinity Biologix maintains its primary operations. This purchase order was issued...
- <p>The National Institute on Drug Abuse (NIDA), a civilian agency, awarded a $24,999.10 firm fixed-price purchase order to Vizioli Omics to complete research and analysis leading to the submission of manuscripts for publication. The contract, which does not have a set-aside designation, has a period of performance through June 24, 2025. This award appears to be for a standalone project and is not associated with a larger contract vehicle.</p>
- The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $150,000.00 firm fixed-price purchase order contract to the New York Stem Cell Foundation Inc., a non-profit organization that conducts stem cell research. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines, differentiating stem cells into insulin-producing beta cells, and expanding and validating neural...
- The National Institute of Drug Abuse awarded a $414,000 firm fixed price definitive contract to New York Stem Cell Foundation Inc. to provide expansion, differentiation, and validation of 36 neural progenitor cell lines derived from induced pluripotent stem cells obtained from subjects with psychiatric conditions. The original solicitation sought proposals to outsource these services within specified timeframes, with an emphasis on technical approach. New York Stem Cell Foundation will...
- The National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), awarded a $16,650.00 firm fixed-price purchase order contract to Novandi Chemistry AB, a manufacturer of goods based in Sweden. The contract is for the delivery of tritiated compounds to support binding experiments investigating novel receptor interactions in vivo. This contract award has no set-aside designation and is not associated with a larger contract vehicle. The contract work...
- The U.S. National Institute on Drug Abuse (NIDA), part of the Department of Health and Human Services' National Institutes of Health, awarded a $19,600.00 Purchase Order contract to Lin Jiunn, a small business located in Ambler, Pennsylvania. The contract is for a Subject Matter Expert Consultant in Drug Metabolism Pharmacokinetics (DMPK) to support NIDA's NIH Blueprint Neurotherapeutics Network program. The contract has a one-year base period with an estimated minimum of 20 annual hours and a...
- The National Institute on Drug Abuse awarded a firm fixed-price purchase order to Rashid Adnan (UEI: LMD7VXK1MQV9) on March 6, 2020, with a ceiling value of $26,900. The contract, which was solicited without a set-aside designation, calls for the awardee to study the pathophysiology and develop related research deliverables, with work to be performed in Greenbelt, Maryland. The solicitation was posted on January 31, 2020, with a bid due date of February 14, 2020, and the contract ultimately...
- This federal contract award was granted by the National Institute on Drug Abuse (NIDA), a civilian agency, to Idea Bio-Medical LTD, a for-profit organization, on September 9, 2015. The contract has a firm fixed price of $122,500.00 and a completion date of October 30, 2015. No set-aside designation was used. The contract type is a purchase order and does not appear to be associated with a larger contract vehicle. The provided information does not indicate any major subcontractors or additional...
- The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $224,000.00 firm fixed price purchase order contract to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for the foundation to provide services including generating induced pluripotent stem cell lines from patients with Alzheimer's disease and related dementias, differentiating stem cells into insulin-producing beta cells, and expanding,...
The National Institute on Drug Abuse (NIDA), a civilian agency, awarded a $183,731.46 firm-fixed-price purchase order contract to Oxford Stemtech LTD for scientific support services related to the generation and multiomics profiling of induced pluripotent stem cell-derived neuronal models. The contract does not have a set-aside designation, and the ultimate completion date is September 10, 2025. This contract award is not associated with a larger acquisition vehicle.
Generated 9/12/24, 10:54 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $183.7k | 9/11/24 |